MilliporeSigma’s Millicell DCI Digital Cell Imager Offers Quick, Accurate, and Objective Cell Monitoring
MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager quickly and objectively assesses common cell culture parameters and growth trends for more consistent cell cultures.
MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager instrument helps improve cell culture productivity in the lab by assessing a broad range of parameters, including confluency, morphology, and cell growth trends, which provides a faster and more accurate analysis with reduced user bias, according to a company press release.
Millicell DCI, launched in October 2021, has an intuitive, built-in touchpad display that enables more efficient execution of repetitive daily laboratory techniques associated with cell passaging, screening, or manufacturing of cell-based products. The Millicell Cloud software operates on an off-device subscription and provides automated data analysis. The software also allows for access to the data from remote desktops or mobile devices. The remote feature saves on costs and supports data redundancy for backup as well as protection by automatically sorting and storing data and images. With this instant access to historical data, researchers can track cell culture trends and create consistent cell cultures.
The instrument also removes the requirement for manual manipulation of the cell culture flask, which can result in reduced contamination risk and improved flexibility users. Evaluation is also possible for a wide variety of cell cultures, including adherent cells and cell lines, spheroids, organoids. In addition, the instrument facilitates hemocytometer or in-vessel measurement.
Source: MilliporeSigma
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
